MyoStrain provided a uniquely sensitive and reproducible measure of segmental heart function to help physicians quantify differences in heart failure patients and risk-stratify patient populations based on the individual extent and severity of dysfunction
MORRISVILLE, N.C., February 11, 2021 – A new article published in the European Society of Cardiology (ESC) Heart Failure Journal demonstrated MyoStrain’s ability to accurately detect and delineate patterns of myocardial dysfunction between heart failure (HF) types and severity.
Conducted as part of the EMPATHY trial in Berlin, Germany (DRKS00015615), the study compared MyoStrain (fast-SENC) against traditional CMR-based cardiac indices, utilizing MyoStrain’s unique segmental strain assessment to describe and differentiate regional dysfunction characteristics between HF patients. HF patients were categorized into reduced, mid-range and preserved ejection fraction cohorts and were assessed at rest using MyoStrain’s MyoHealth™ risk score, as well as circumferential and longitudinal strain data provided via the MyoStrain report.
Results showed that while traditional cardiac indices did not delineate myocardial dysfunction between patients, MyoStrain was able to successfully detect and differentiate myocardial function impairment among the different HF groups and the control group. MyoStrain also detected regional dysfunction occurring along the ventricular septum, even when left-ventricular ejection fraction was preserved, demonstrating MyoStrain’s ability to discriminate between impaired and affected segments as they occur regionally throughout the myocardium.
Sebastian Kelle, MD, PhD, FSCMR, Head of Cardiac Imaging at the Berlin Center and the study’s primary investigator, commented: “The study highlights the importance of using both longitudinal and circumferential strain to assess myocardial deformation in cardiac patients. This makes MyoStrain a critical tool for physicians to evaluate cardiac patients, as it uses both of these metrics in a single MyoHealth™ risk score. This information may help to guide individualized treatment decisions and potentially mitigate future dysfunction progression by monitoring the functional effects of treatment on the heart over time.”
Full access to the publication is available here.
 Hashemi, D., et al. (2021) Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. ESC Heart Failure, https://doi.org/10.1002/ehf2.13193
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.